Sana Biotechnology, Inc. — Form 8-K Summary
Business context and reporting period
Sana Biotechnology, Inc. filed a Form 8-K under Item 5.02 regarding executive compensation decisions. The Board and Compensation Committee approved the actions on February 24–25, 2021; the report was signed March 2, 2021. The compensation data covers the fiscal year ended December 31, 2020.
Executive compensation and key metrics
| Executive | 2020 total compensation | 2021 base salary | 2021 target bonus | 2021 discretionary bonus |
|---|---|---|---|---|
| Steven D. Harr, M.D., President and CEO | $6,845,197 | $625,000 | 60% | $200,000 |
| Richard Mulligan, Ph.D., Executive Vice-Chairman and Head of SanaX | $2,098,811 | $463,500 | 40% | $10,000 |
| Christian Hordo, Executive Vice President and Chief Business Officer | $1,590,373 | $403,000 | 40% | $50,000 |
The 2020 compensation totals included salary, option awards, non-equity incentive compensation and, for Dr. Mulligan, other compensation. The filing does not provide revenue, profit, cash flow, margins, debt, liquidity or other operating-performance metrics.
- 2020 performance cash bonuses were approved for the named executive officers, but the filing’s reproduced compensation table does not separately identify the applicable bonus amount beyond the reported compensation categories.
- 2021 salaries and target bonus opportunities became effective February 22, 2021.
- The 2021 discretionary bonuses were scheduled for payment on March 5, 2021.
Material changes, outlook and risks
The filing does not discuss changes versus a prior comparable financial period, business guidance, operating outlook, contingencies or company-specific risks. Its principal disclosure is the increase or establishment of 2021 executive compensation arrangements and the reporting of 2020 compensation.
Notable unusual compensation items include Dr. Harr’s $6,015,947 of 2020 option-award grant-date fair value and $337,780 of principal and accrued interest on a promissory note forgiven for Dr. Mulligan in November 2020. Dr. Mulligan’s reported 2020 salary included $124,443 earned as a consultant before becoming an employee in April 2020.
Important facts for investors to verify
- Verify the payment and accounting treatment of the 2021 discretionary bonuses.
- Review the Form S-1 and related financial statements for the assumptions underlying the reported option-award fair values.
- Confirm the employment, consulting and compensation arrangements for Dr. Mulligan, including the forgiven promissory note.
- Consult the company’s periodic financial filings for cash balances, liquidity, operating expenses, financing needs and development-program risks, which are not addressed in this 8-K.